BioNexus Gene Lab Corp
BGLC · XNASCIK 1737523fmd_1T0BN11D99MRWTEP9NRJK89EFNServices · Services-Medical LaboratoriesTemplate: Standard
Coverage: Jan 01, 2018 to Jun 30, 2026, 34 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 11 | 13 | 11 | 10 | 10 | 7 |
| Cost of revenue | (0) | 0 | 10 | 11 | 10 | 8 | 8 | 6 |
| Net interest income | – | – | – | – | 0 | 0 | – | – |
| Gross profit | 0 | 0 | 2 | 2 | 1 | 1 | 1 | 1 |
| Realized investment gains (losses) | – | 0 | 0 | 0 | – | – | – | – |
| Provision for credit losses | – | – | – | – | – | (1) | (1) | (0) |
| Net interest income after provision | – | – | – | – | – | 1 | – | – |
| Research and development | – | – | – | – | – | 0 | 0 | 0 |
| Selling, general and administrative | – | – | – | – | – | 3 | 4 | 3 |
| Total operating expenses | – | – | – | – | – | (4) | 5 | 4 |
| Operating income | 0 | (0) | 1 | 1 | (0) | (3) | (2) | (3) |
| Interest expense | – | – | – | – | 0 | 0 | – | – |
| Interest and investment income | – | – | (0) | – | – | – | – | – |
| Other non-operating income (expense) | (0) | 0 | – | – | – | 0 | 2 | 0 |
| Income before taxes | – | – | – | 1 | (0) | (3) | (2) | (3) |
| Income tax expense | (0) | 0 | – | (0) | (0) | (0) | (0) | 0 |
| Net income from continuing operations | – | – | – | 1 | (0) | (3) | (2) | (3) |
| Net income | 0 | (0) | 1 | 1 | (0) | (3) | (2) | (3) |
| Net income to common shareholders | – | (0) | – | – | – | (3) | (2) | (3) |